Hsp90 inhibition sensitizes DLBCL cells to cisplatin

ConclusionThis study demonstrates that 17AAG sensitizes DLBCL cells to cisplatin treatment. This effect is correlated with increased apoptotic and DNA damage response, potentially mediated by downregulation of Hsp90 clients in DNA repair pathways. Thus, cisplatin resistance could plausibly be overcome by combining the treatment with an Hsp90 inhibiting drug.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research